TREATMENT 
SIGNING DAY
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable
For the Unstoppable

Rethinking your hem B treatment is better with confetti

Treatment Signing Day is the debatably real event where guys reconsider their treatment choices and decide what works for them. Always talk to your doctor about treatment decisions that are best for you.
On Demand

On Demand
Treatment On Demand

Treatment When You Need It?
now We’re Talking.

On Demand

Those
Numbers
Below
Actually Say
Big Things On Demand

In adults and adolescents 12 years and older, 9 out of 10 bleeds were treated with just one infusion (n=575/636 bleeds)

90.4% of bleeds were treated with just one infusion
97.3% of bleeds were treated with 2 or fewer infusions
100% of bleeds were treated with 3 or fewer infusions

The median overall bleed rate (ABR) for adults and adolescents who treated On Demand was 17.69.

B-LONG was a phase 3 study that investigated the safety and efficacy of ALPROLIX in 123 previously treated adult and adolescent patients with severe hemophilia B. The study included a fixed-interval arm (n=61), a fixed-dose arm (n=26), an episodic arm (n=27), and a surgical arm (n=12).

On Demand

FOR FANS OF
LOGO REVEALS
AND RESULTS On Demand

In 84% of bleeding episodes, adults and adolescents experienced pain relief and/or improvement in signs of bleeding with just one infusion (n=513/613 bleeds).

*Responses are based on number of first injections for a bleeding episode with an evaluation. Excellent response was defined as abrupt pain relief and/or improvement in signs of bleeding. Good response was defined as definite pain relief and/or improvement in signs of bleeding but possibly requiring another injection in 1-2 days.

Treatment Signing Day
Play-by-Play

The decision is in and it's ALPROLIX all around! Sign up to receive information about future Treatment Signing Day Play-by-Play events to look back at Treatment Signing Day and learn more about ALPROLIX as a treatment option.
Sign Up Now

GET THE 411 ON
ALPROLIX SAFETY

SELECTED IMPORTANT SAFETY
INFORMATION

In the clinical studies of 153 previously treated people, adverse reactions occurred in 14 participants (9.2%).

In the clinical study of 33 previously untreated people, adverse reactions occurred in 2 participants (6.1%).

The most common side effects in previously treated patients were headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system, occurred in two people each.

In a study of previously untreated patients who were treated with ALPROLIX, 2 of 33 had adverse drug reactions. One person in the study developed a Factor IX inhibitor and the same person developed an allergic reaction. One additional person in the study developed redness to the skin at the injection site.

These are not all of the possible side effects of ALPROLIX.

Prophy

Prophy
Treatment Prophy

Staying Ahead Of Bleeds?
Now We're Talking

Prophy

For Fans Of Protection* Prophy

Adults And Adolescents
Experienced Bleed And
Joint Bleed Protection

Adults and Adolescents on a prophylactic regimen experienced a median of:
  • 1.38 overall bleeds per year on a prophy individualized interval (n=26)
  • 2.95 overall bleeds per year on a prophy fixed weekly interval (n=61)
  • ~1 or fewer spontaneous bleeds per year
*ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
In the B-LONG study, adults and adolescents infusing prophylactically experienced a median of:

0.36 joint bleeds per year on a prophy individualized interval (n=26)

1.11 joint bleeds per year on a prophy fixed weekly interval (n=61)

In the B-LONG study, adults and adolescents who started infusing on a 10-day individualized prophylaxis regimen with ALPROLIX experienced a median annual spontaneous bleed rate (AsBR) of 0.9 bleeds per year. The overall median annual bleed rate (ABR) was 1.4 bleeds per year (n=26).

In the same study, adults and adolescents infusing on a once-weekly prophylaxis regimen with ALPROLIX experienced a median AsBR of 1.04 bleeds per year. The overall median ABR was 3 bleeds per year (n=61).

Prophy

A HAT CAN
SAY A
LOT
ABOUT A GUY Prophy

100% Target Joint
Resolution in 37 adults and adolescents

37/37 patients with target joints at the baseline of the B-LONG study achieved target joint resolution with ALPROLIX during the extension study. These subjects had ≥12 months of consecutive follow-up time and did not undergo joint surgery within 12 months of the start of follow-up.

A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 3-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.

It all starts
when you 
sign up

Ready to learn more about ALPROLIX as a treatment option? Drop your info below to sign up for upcoming Treatment Signing Day Play-by-Play events.

Plus, when you sign up you’ll be all set to receive email updates from ALPROLIX and a Bluetooth Speaker to listen to ALPROLIX patient stories, or a cooler bag if you’re already on ALPROLIX.*

*You have to be a patient and/or a caregiver in order to receive either a Bluetooth speaker or a cooler bag
×

INDICATION: ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

important safety information and indication 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.

INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

important safety information and indication 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.

INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

Please see full Prescribing Information

MANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, ET

© 2021 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

MAT-US-2021804-v3.0-06/2021 LAST UPDATED: JUNE 2021

© 2021 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

MAT-US-2021804-v3.0-06/2021 LAST UPDATED: JUNE 2021

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, ET